FAIRFIELD, N.J.--(BUSINESS WIRE)--Sept. 19, 2006--Unigene
Laboratories, Inc.'s (OTCBB: UGNE) President and CEO, Dr. Warren Levy,
will speak at the 8th Annual UBS Global Life Sciences Conference on
Wednesday, September 27, 2006 at 11:00 A.M. Dr. Levy will present
information on Unigene's products and collaborations to analysts,
portfolio managers, investment bankers and other financial
professionals. The conference will be held at The Grand Hyatt in New
York City from September 25-28, 2006.
A live audio webcast of the presentation will also be available on
the UBS website at www.ibb.ubs.com under the "conference" tab. An
audio replay of the presentation will begin three hours after the
presentation time and will be available until October 28, 2006.
About Unigene
Unigene Laboratories, Inc. is a biopharmaceutical company focusing
on the oral and nasal delivery of large-market peptide drugs. Due to
the size of the worldwide osteoporosis market, Unigene is targeting
its initial efforts on developing calcitonin and PTH-based therapies.
Fortical(R), Unigene's nasal calcitonin product for the treatment of
postmenopausal osteoporosis, received FDA approval and was launched in
August 2005. Unigene has licensed the U.S. rights for Fortical(R) to
Upsher-Smith Laboratories, worldwide rights for its oral PTH
technology to GlaxoSmithKline and worldwide rights for its calcitonin
manufacturing technology to Novartis. Unigene's patented oral delivery
technology has successfully delivered, in preclinical and/or clinical
trials, various peptides including calcitonin, PTH and insulin.
Unigene's patented manufacturing technology is designed to
cost-effectively produce peptides in quantities sufficient to support
their worldwide commercialization as oral or nasal therapeutics. For
more information about Unigene, call (973) 882-0860 or visit
www.unigene.com. For information about Fortical, visit
www.fortical.com.
Safe Harbor statements under the Private Securities Litigation
Reform Act of 1995: This press release contains forward-looking
statements as defined in Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Such forward-looking statements are based upon Unigene
Laboratories, Inc.'s management's current expectations, estimates,
beliefs, assumptions, and projections about Unigene's business and
industry. Words such as "anticipates," "expects," "intends," "plans,"
"predicts," "believes," "seeks," "estimates," "may," "will," "should,"
"would," "potential," "continue," and variations of these words (or
negatives of these words) or similar expressions, are intended to
identify forward-looking statements. In addition, any statements that
refer to expectations, projections, or other characterizations of
future events or circumstances, including any underlying assumptions,
are forward-looking statements. These forward-looking statements are
not guarantees of future performance and are subject to certain risks,
uncertainties, and assumptions that are difficult to predict.
Therefore, our actual results could differ materially and adversely
from those expressed in any forward-looking statements as a result of
various risk factors. These risks and uncertainties include the risks
associated with the effect of changing economic conditions, trends in
the products markets, variations in Unigene's cash flow, market
acceptance risks, technical development risks and other risk factors
detailed in Unigene's Securities and Exchange Commission filings.
CONTACT: Unigene Laboratories, Inc.
Investors:
The Investor Relations Group
Damian McIntosh or Dian Griesel, Ph.D., 212-825-3210
or
Media:
Susan Morgenbesser, 212-825-3210
SOURCE: Unigene Laboratories, Inc.
|
